Clinical trials are currently investigating psilocybin therapy, as a treatment for depression at research centres around the world. This webinar gives valuable insight into the benefits of psilocybin treatment, from the perspective of a patient who suffered from depression for most of his adult life.
Michael Bourne is a 57-year-old website designer from the North East of England, who tried several unsuccessful depression treatments, including talking therapy and prescription medications, before turning to psilocybin clinical trials.
Michael took part in research into psilocybin treatment for depression in 2015 as part of the clinical trial at Imperial College London. He was transformed and invigorated as a result. The positive effect of psilocybin therapy lasted for almost a year, and has continued to help keep daily life in perspective. Psilocybin treatment has hugely helped him regain his passion for creativity in audio and photography/graphic design.
He is currently on the steering committee for the Kings College research into psilocybin therapy for treatment resistant depression. This clinical trial (PsiDeR) is due to start early 2021, and will compare psilocybin therapy to a placebo. Michael is driven to help others who suffer with depression because of how much psilocybin has helped him.
If you’d like to learn more about psilocybin, including the medical applications for which it is currently being studied, check out our Medical Psilocybin Educational Modules.
This webinar was part of the Student Psychedelic Conference which took place on the 30th – 31st of January 2021.
The conference was hosted by The Students for Sensible Drug Policy, Drug Science Student Society, and The Southampton Psychedelic Society.
Drug Science is the leading independent scientific body on drugs in the UK. We rely on donations to provide clear, evidence-based information without political or commercial interference. Drug Science webinars are free, so if you’d like to support us then please consider joining the Drug Science Community.